

Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions

<https://marketpublishers.com/r/G0291966F87EN.html>

Date: December 2018

Pages: 288

Price: US\$ 1,375.00 (Single User License)

ID: G0291966F87EN

Abstracts

Report Scope:

The report on “Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions” presents qualitative and quantitative information on the current market dynamics that are influencing the market. It covers a background to cancer, types of cancer, pathogenesis of cancer, and stages of cancer development, including the mechanisms of metastasis and recurrences. It also includes the disease burden through understanding the epidemiology of various cancers. Treatment patterns, which include the pharmacological approaches (covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy, and combinatorial therapy) and non-pharmacological approaches (including surgeries and radiation) are covered to present the various therapeutic options available for the patients. Also included in the report are analyses of key marketed products; the current clinical trial landscape; patent landscape and recent product approvals; regulatory landscape; and reimbursement landscape across different demographics. An overview of the demographics of key regions, namely, North America, Europe, Asia-Pacific, Latin America and the Middle East, with potential growth is also covered. Strategies of global companies engaged in the cancer therapeutic space and the profiles of top companies are also covered.

The quantitative information covered in the report includes -

Estimates of the market size of the cancer therapeutics used for treating metastases and recurrence states of cancer. The key cancer types covered include lung cancer, breast cancer, liver cancer, stomach cancer, prostate cancer, colorectal cancer, gastric cancer, cervical cancer, bladder cancer, kidney cancer, ovarian cancer and others. Others includes leukemia, lymphoma,

multiple myeloma, brain tumor, thyroid cancer and uteral cancer.

Further growth potential and forecast information has been covered for the overall cancer therapeutics market and for segments-cancer types, by region and by country.

Market values provided are based on total revenues of cancer therapeutics drug manufacturers.

As a cancer therapeutics (emphasis on recurrent and metastatic cancer) market report, only pharmacological therapy is covered for computation of the market size. Interventions involving surgeries, radiation, ablations and other medical device interventions are excluded from the market size computation and only qualitative information on the same is covered.

Report Includes:

36 data tables and 55 additional tables

An overview of global cancer therapeutics market with special focus on recurrent and metastatic divisions

Country specific data and analysis for US, Canada, Mexico, Germany, Italy, U.K, France, China, India, Japan, South Korea, Brazil, Argentina and Chile

Description of stages of cancer development including the mechanisms of metastasis and recurrences

Insights of current diagnostics such as medical imaging, in vitro diagnostics technologies and treatment patterns

Snapshot of pharmacological approaches covering cytotoxic/chemotherapy, hormonal therapy, targeted therapy and combinatorial therapy and non-pharmacological treatments such as surgeries, radiation

Complete understanding of causes, risk factors, prevalence and incidence of cancer

Information on economic cost burden due to cancer

Dossier of recent industry events, product innovation, acquisition, partnership and collaborations and competitor strategies

Comprehensive company profiles of major market players of the industry including AbbVie, Inc., Biogen Inc., GlaxoSmithKline plc (GSK), Eli Lilly and Co., Merck & Co., Inc., and Pfizer Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Scope of Report
Information Sources
Methodology
Market Estimation and Forecast
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY

Key Findings

CHAPTER 3 BIOLOGY OF CANCER

Overview
Lung Cancer
Breast Cancer
Melanoma
Colorectal Cancer
Prostate Cancer
Cervical Cancer
Pathogenesis of Cancer
Genetic Changes
Stages of Cancer
The TNM Staging System
Number Staging Systems
Cancer Metastases
Routes of Metastasis
Drug Resistance
Inherent Resistance
Acquired Resistance

CHAPTER 4 DISEASE AND ECONOMIC BURDEN OF CANCER

Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions

Cancer Burden

Tobacco Use and Statistics

Alcohol Abuse and Cancer Statistics

Infectious Diseases and Cancer

Inherited Genes/Diseases and Cancer

Sun, Ultraviolet Radiation and Cancer

Hormones and Cancer

Cancer: A Statistical Analysis of the Disease Incidence and Prevalence

Incidence and Prevalence Rates for Major Cancer Types

Regional Patterns of Cancer

Europe

North America

Asia-Pacific

Latin and Central America

Middle East and Africa

CHAPTER 5 TREATMENT APPROACHES TO CANCER METASTASES AND RECURRENCE

Treatment Approaches to Cancer Metastases and Recurrence

Non-pharmaceutical Approaches

Surgery for Cancer

Radiotherapy for Cancer

Ablation Therapy

Pharmacological Therapies

Cytotoxic Cancer Chemotherapy

Hormone-based Cancer Drugs

Targeted Biologic Therapy

Monoclonal Antibodies

Immune Checkpoint Inhibitors

Cancer Growth Blockers

Gene Therapy

Drugs That Block Cancer Blood Vessel Growth (Antiangiogenics)

Personalized Cancer Therapy (Precision Medicine)

Treatment Options for Selected Cancer Metastases

Breast

Bladder Cancer

Lung

Colorectal Cancer
Standard Treatment Options for Stage IV and Recurrent Colon Cancer
Prostate Cancer
Stomach Cancer
Melanoma
Kidney Cancer
Transitional Cell Cancer (TCC) of the Renal Pelvis and Ureter
Pancreatic Cancer
Thyroid Cancer
Stage I and Stage II Endometrial Cancer
Stage III, Stage IV and Recurrent Endometrial Cancer

CHAPTER 6 CANCER THERAPEUTICS: MARKETED PRODUCTS AND PIPELINE ANALYSIS

Overview
Top Selling Oncology Drugs in 2017
Profiles of Selected Marketed Drugs
Clinical Trials
Lung Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trial
Breast Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials
Colorectal Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials
Bladder Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials
Gastric Cancer
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials

Others (Kidney Cancer, Lymphoma, Leukemia, Ovarian, Pancreatic)
Phase III Clinical Trials
Phase II Clinical Trials
Phase I Clinical Trials

CHAPTER 7 REGULATIONS AND REIMBURSEMENT LANDSCAPE

The United States

Canada

Europe

Mutual Recognition Procedure (MRP)

Decentralized Procedure (DCP)

Centralized Procedure (CP)

Japan

Marketing Authorization System

Pharmaceutical Reimbursement Approval Process in Japan

China

Pharmaceutical Regulatory and Legislative Developments in China

India

Pharmaceutical Regulatory and Legislative Developments in India

South Korea

Regulatory and Legislative Requirements

Pharmaceutical Regulatory and Legislative Developments in South Korea

Pharmaceutical Reimbursement Landscape in South Korea

Brazil

Market Entry and Reimbursement of Pharmaceuticals

Argentina

Regulatory and Legislative Requirements

Mexico

Regulation and Regulation Governing Drugs in Mexico

Health Insurance Structure in Mexico

South Africa

Regulatory Requirements in South Africa

Health Insurance Structure in South Africa

Reimbursement of Pharmaceuticals in South Africa

Saudi Arabia

Pharmaceutical Regulatory Requirements in Saudi Arabia

Health Insurance Structure in Saudi Arabia

CHAPTER 8 CANCER THERAPEUTICS: ANALYSIS OF GLOBAL AND REGIONAL MARKETS

Overview

Global Cancer Therapeutics Market

Market Drivers

Market Restraints

Market Opportunities

North America

Market Dynamics in North America

United States

Canada

Europe

Market Drivers

Market Restraints

France

Germany

U.K.

Spain

Italy

Asia-Pacific

Market Drivers

Market Restraints

Japan

China

India

Central and Latin America

Market Drivers

Market Restraints

Brazil

Argentina

Middle East and Africa

Market Drivers

Market Restraints

CHAPTER 9 PATENT REVIEW/NEW DEVELOPMENTS

Patent Applications by Clinical Application

Patent Applications Filed on Metastatic Breast Cancer Therapeutics

Patent Applications Filed on Metastatic Prostate Cancer Therapeutics

Patent Applications Filed on Metastatic Lung Cancer Therapeutics

Patents Applications Filed on Therapeutics for Other Cancer Types

Patents and Expiry Dates for Major Products by Leading Suppliers

Pfizer Inc.

Merck & Co.

Johnson & Johnson

F Hoffman-La Roche

Sanofi SA

Novartis AG

AbbVie, Inc.

AstraZeneca plc

Celgene

Eli Lilly

Gilead Sciences

Patents and Expiry Dates for Other Products and Suppliers

Targeting Breakpoint Cluster Region-Abelson (BCR-ABL)

Targeting Epidermal Growth Factor Receptor (EGFR/ERBB1)

Targeting Vascular Endothelial Growth Factor Receptor (VEGFR), PDGFR and Ret Proto-Oncogene (RET)

Impact of Patent Expiries

CHAPTER 10 COMPETITIVE LANDSCAPE

Overview

Leading Companies

Roche

Novartis

Celgene

Bristol-Meyers Squibb

Johnson & Johnson

Recent Developments

CHAPTER 11 COMPANY PROFILES

ABBVIE, INC.

Company Overview

Financial Information

Products

Clinical Developments

AMGEN

Company Overview

Financial Information

Products

ARRAY BIOPHARMA INC.

Company Overview

Products

AstraZeneca plc

Company Overview

Financial Information

Key Developments

ASTELLAS PHARMA INC.

Company Overview

Products

BAYER HEALTHCARE

Company Overview

Products

BRISTOL-MYERS SQUIBB

Company Overview

Financial Information

Products

BIOGEN INC.

Company Overview

CELGENE CORP.

Company Overview

Financial Information

Products

CELLDEX THERAPEUTICS INC.

Company Overview

Products

GLAXOSMITHKLINE

Company Overview

GILEAD SCIENCES, INC.

Company Overview

Product

ELI LILLY AND CO.

Company Overview

Financial Information

Products

EISAI CO. LTD.

Company Overview

Products

F HOFFMAN-LA ROCHE LTD.

Company Overview

Financial Information

Products

Key Developments

IMMUNOCELLULAR THERAPEUTICS LTD.

Company Overview

Products

IMMUNOGEN INC.

Company Overview

INCYTE CORP.

Company Overview

INFINITY PHARMACEUTICALS, INC.

Company Overview

JOHNSON & JOHNSON

Company Overview

Financial Information

Products

MERCK & CO., INC.

Financial Information

Products

NOVARTIS AG

Company Overview

Financial Information

Products

Clinical Development

Key Developments

NEW LINK GENETICS CORP.

Company Overview

OTSUKA HOLDINGS CO. LTD.

Company Overview

PFIZER INC.

Company Overview

Financial Information

Key Developments

REGENERON PHARMACEUTICALS INC.

Company Overview

SANOFI SA

Company Overview

Financial Information

Products

Key Developments

SELLAS LIFE SCIENCES GROUP

Company Overview

TAKEDA PHARMACEUTICALS

Company Overview

VERASTEM INC.

Company Overview

CHAPTER 12 APPENDIX: ACRONYMS

List Of Tables

LIST OF TABLES

Summary Table: Global Cancer Therapeutics Market, by Cancer Type, Through 2023

Table 1: Cancer Incidence in the U.S., by Sex, 2017

Table 2: Number of Deaths from Cancer in the U.S., by Sex, 2017

Table 3: Cancer Treatment Options

Table 4: Cancer Drug Treatment Classes

Table 5: FDA-Approved Intravenous Therapeutic Monoclonal Antibodies Used to Treat Cancer, 1997-2017

Table 6: Approved Tyrosine Kinase Inhibitors (TKIs) Used to Treat Cancer

Table 7: Common Chemotherapeutic Agents for Recurrent and Metastatic Breast Cancer

Table 8: Drugs Approved for the Treatment of Lung Cancer

Table 9: Treatment Options for Stage IV and Recurrent Colon Cancer

Table 10: Hormone Therapy for Prostate Cancer

Table 11: Drugs Approved for Prostate Cancer

Table 12: Drugs Approved for Stomach (Gastric) Cancer

Table 13: Drugs Combinations Approved for Stomach (Gastric) Cancer

Table 14: Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors

Table 15: Drugs Approved for the Treatment of Melanoma

Table 16: Drugs Approved for Pancreatic Cancer

Table 17: Drugs Approved for Pancreatic Cancer

Table 18: Treatment Option Overview for Thyroid Cancer

Table 19: Drugs Approved for Thyroid Cancer

Table 20: Treatment Option Overview for Endometrial Cancer

Table 21: Profiles of Top Marketed Drugs

Table 22: Lung Cancer Phase III Clinical Trials, 2018*

Table 23: Lung Cancer Phase II Clinical Trials, 2018*

Table 24: Lung Cancer Phase I Clinical Trials, 2018*

Table 25: Breast Cancer Phase III Clinical Trials, 2018*

Table 26: Breast Cancer Phase II Clinical Trials, 2018*

Table 27: Breast Cancer Phase I Clinical Trials, 2018*

Table 28: Colorectal Cancer Phase III Clinical Trials, 2018*

Table 29: Colorectal Cancer Phase II Clinical Trials, 2018*

Table 30: Colorectal Cancer Phase I Clinical Trials, 2018*

Table 31: Bladder Cancer Phase III Clinical Trials, 2018*

Table 32: Bladder Cancer Phase II Clinical Trials, 2018*

- Table 33: Bladder Cancer Phase I Clinical Trials, 2018*
- Table 34: Gastric Cancer Phase III Clinical Trials, 2018*
- Table 35: Gastric Cancer Phase II Clinical Trials, 2018*
- Table 36: Gastric Cancer Phase I Clinical Trials, 2018*
- Table 37: Others Phase III Clinical Trials, 2018*
- Table 38: Others Phase II Clinical Trials, 2018*
- Table 39: Others Phase I Clinical Trials, 2018*
- Table 40: Global Cancer Therapeutics Market, by Cancer Type, Through 2023
- Table 41: North American Cancer Therapeutics Market, by Cancer Type, Through 2023
- Table 42: North American Cancer Therapeutics Market, by Country, Through 2023
- Table 43: European Cancer Therapeutics Market, by Cancer Type, Through 2023
- Table 44: European Cancer Therapeutics Market, by Country, Through 2023
- Table 45: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, Through 2023
- Table 46: Asia-Pacific Cancer Therapeutics Market, by Country, Through 2023
- Table 47: Central and Latin American Cancer Therapeutics Market, by Cancer Type, Through 2023
- Table 48: Central and Latin American Cancer Therapeutics Market, by Country, Through 2023
- Table 49: Middle East and Africa Cancer Therapeutics Market, by Cancer Type, Through 2023
- Table 50: Patent Applications Filed on Metastatic Breast Cancer Therapeutics, 2016 – October 2017
- Table 51: Patent Applications Filed on Metastatic Prostate Cancer Therapeutics, November 2015 – January 2018
- Table 52: Patent Applications Filed on Metastatic Lung Cancer Therapeutics, August 2015 – January 2018
- Table 53: Latest Patent Publications Cited Relating to Other Metastatic Cancers, December 2015 – July 2018
- Table 54: Pfizer Inc.: Patent Expiry Dates for Leading Cancer Drugs
- Table 55: Merck & Co.: Patent Status of Leading Oncology Products
- Table 56: Johnson & Johnson: Patent Status of Leading Oncology Products
- Table 57: F Hoffman-La Roche: Patent Status of Leading Oncology Products
- Table 58: Sanofi SA: Patent Status of Leading Oncology Products
- Table 59: AstraZeneca plc: Patent Status of Leading Oncology Products
- Table 60: Celgene: Patent Status of Leading Oncology Products
- Table 61: Eli Lilly: Patent Status of Leading Oncology Products
- Table 62: Recent Industry Developments, December 2017 Through September 2018
- Table 63: AbbVie, Inc.: Company Financials, by Product, 2015-2017
- Table 64: Amgen: Company Financials, 2015-2017

- Table 65: Array Biopharma Inc.: Clinical Stage Drug Portfolio
- Table 66: AstraZeneca plc.: Company Net Revenue, 2015-2017
- Table 67: AstraZeneca plc: Company Financials, by Therapeutic Product Group, 2015-2017
- Table 68: AstraZeneca plc: Company Financials, by Oncology Product Group, 2015-2017
- Table 69: Bristol-Myers Squibb: Revenue, 2015-2017
- Table 70: Bristol-Myers Squibb: Oncology Product Sales, 2015-2017
- Table 71: Celgene Corp.: Company Financials, by Product, 2015-2017
- Table 72: GlaxoSmithKline: Oncology Product Pipeline
- Table 73: Gilead Sciences, Inc.: Product Pipeline
- Table 74: Eli Lilly and Co.: Net Revenue, by Segment, 2015-2017
- Table 75: Eli Lilly and Co.: Oncology Product Sales, 2015-2017
- Table 76: F Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2015-2017
- Table 77: F Hoffman-La Roche Ltd.: Pharmaceutical Division Oncology Product Sales, 2015-2017
- Table 78: Johnson & Johnson: Company Financials, by Segment, 2015-2017
- Table 79: Johnson & Johnson: Pharmaceutical Therapeutic Area Product Sales, 2015-2017
- Table 80: Johnson & Johnson: Oncology Product Sales, 2015-2017
- Table 81: Merck & Co., Inc.: Therapeutic Area Product Sales, 2015-2017
- Table 82: Merck & Co., Inc.: Oncology Product Sales, 2015-2017
- Table 83: Novartis AG: Company Financials, by Business Segment, 2015-2017
- Table 84: Novartis AG: Major Development Projects
- Table 85: Pfizer Inc.: Company Financials, 2015-2017
- Table 86: Pfizer Inc.: Innovative Health (IH) Division Financials, 2015-2017
- Table 87: Pfizer Inc.: Innovative Health (IH) Division Oncology Product Sales, 2015-2017
- Table 88: Sanofi SA: Company Financials, 2015-2017
- Table 89: Sanofi SA: Oncology Product Sales, 2015-2017
- Table 90: Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer

List Of Figures

LIST OF FIGURES

Summary Figure: Global Cancer Therapeutics Market Share, by Cancer Type, 2017

Figure 1: Top Selling Oncology Drugs, 2017

Figure 2: Distribution of Clinical Trials for Cancer Metastases and Recurrence, by Cancer Type, 2018*

Figure 3: Global Cancer Therapeutics Market, 2017-2023

Figure 4: Global Cancer Therapeutics Market Share, by Cancer Type, 2017

Figure 5: North American Cancer Therapeutics Market, by Cancer Type, 2017-2023

Figure 6: European Cancer Therapeutics Market, by Cancer Type, 2017-2023

Figure 7: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, 2017-2023

Figure 8: Central and Latin American Cancer Therapeutics Market, by Cancer Type, 2017-2023

Figure 9: Middle East and African Cancer Therapeutics Market, by Cancer Type, 2017-2023

Figure 10: Global Cancer Therapeutics Market Share, by Company, 2017

I would like to order

Product name: Global Cancer Therapeutics Market: Emphasis on Recurrent and Metastatic Divisions

Product link: <https://marketpublishers.com/r/G0291966F87EN.html>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0291966F87EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970